Apolipoprotein A-IV concentrations and clinical outcomes in a large chronic kidney disease cohort: Results from the GCKD study.

Johannes P SchwaigerBarbara KolleritsInga SteinbrennerHansi WeissensteinerSebastian SchönherrLukas ForerFruzsina KotsisClaudia LaminaMarkus P SchneiderUlla T SchultheissChristoph WannerAnna KöttgenKai-Uwe EckardtFlorian Kronenbergnull null

Published in: Journal of internal medicine (2022)

These data support a link between elevated apoA-IV concentrations and reduced inflammation in moderate CKD. ApoA-IV appears to be an independent risk marker for reduced all-cause mortality, cardiovascular events and heart failure in a large cohort of patients with CKD.

Keyphrases

chronic kidney disease
cardiovascular events
end stage renal disease
heart failure
coronary artery disease
cardiovascular disease
oxidative stress
left ventricular
atrial fibrillation
type diabetes
big data
breast cancer risk